bioMerieux SA (BIOX.PA)

BIOX.PA

About

bioMerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.28
Market Cap (Mil.):	€2,876.57
Shares Outstanding (Mil.):	39.45
Dividend:	0.98
Yield (%):	1.34

Financials

	BIOX.PA	Industry	Sector
P/E (TTM):	21.38	28.54	32.18
EPS (TTM):	3.41	--	--
ROI:	10.80	9.72	18.91
ROE:	11.74	13.06	19.87

Latest News about BIOX.PA

» More BIOX.PA News

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
bioMerieux SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Wright Investors Service Comprehensive Report for Biomerieux SA Provider: Wright Reports	$472.00 Buy
bioMerieux S.A. (BIM) - Medical Equipment - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
bioMerieux SA Provider: Datamonitor	$175.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Stocks
Stock Screener
Market Data
Healthcare
Medical Equipment / Supplies / Distribution

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.